RT Journal Article SR Electronic T1 Preferential expansion upon boosting of cross-reactive “pre-existing” switched memory B cells that recognize the SARS-CoV-2 Omicron variant Spike protein JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.12.30.21268554 DO 10.1101/2021.12.30.21268554 A1 Perugino, Cory A. A1 Liu, Hang A1 Feldman, Jared A1 Hauser, Blake M. A1 Jacob-Dolan, Catherine A1 Nathan, Anusha A1 Zhou, Zezhou A1 Kaseke, Clarety A1 Tano-Menka, Rhoda A1 Getz, Matthew A. A1 Senjobe, Fernando A1 Berrios, Cristhian A1 Ofoman, Onosereme A1 Lemieux, Jacob E. A1 Goldberg, Marcia B. A1 Nundel, Kerstin A1 Moormann, Ann A1 Marshak-Rothstein, Ann A1 Iafrate, John A. A1 Gaiha, Gaurav A1 Charles, Richelle A1 Balazs, Alejandro B. A1 Naranbhai, Vivek A1 Schmidt, Aaron G. A1 Pillai, Shiv YR 2022 UL http://medrxiv.org/content/early/2022/01/01/2021.12.30.21268554.abstract AB In previously unvaccinated and uninfected individuals, non-RBD SARS-CoV-2 spike-specific B cells were prominent in two distinct, durable, resting, cross-reactive, “pre-existing” switched memory B cell compartments. While pre-existing RBD-specific B cells were extremely rare in uninfected and unvaccinated individuals, these two pre-existing switched memory B cell compartments were molded by vaccination and infection to become the primary source of RBD-specific B cells that are triggered by vaccine boosting. The frequency of wild-type RBD-binding memory B cells that cross-react with the Omicron variant RBD did not alter with boosting. In contrast, after a boost, B cells recognizing the full-length Omicron variant spike protein expanded, with pre-existing resting memory B cells differentiating almost quantitatively into effector B cell populations. B cells derived from “ancient” pre-existing memory cells and that recognize the full-length wild-type spike with the highest avidity after boosting are the B cells that also bind the Omicron variant spike protein.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by NIH U19 AI110495 to SP and the Massachusetts Consortium on Pathogen Readiness and the UMASS Covid Research Fund. The graphical abstract was prepared using Biorender.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was performed with the approval of the Institutional Review Boards at the Massachusetts General Hospital and the University of Massachusetts Medical School.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the corresponding author.